TheEdgeResearch
Home / Stocks / VTIAF

FamiCord AG (VTIAF)

OTC Healthcare Biotechnology
$6.38 ▲ +0.00%
Market Cap
$111.1M
Sector
Healthcare
Industry
Biotechnology
Beta
0.56
52-Wk Range
5.5-7
CEO
Jakub Julian Baran
Country
DE
Currency
USD

FamiCord AG operates in the Biotechnology industry of the Healthcare sector, headquartered in Leipzig, SX, DE. The stock last traded at $6.38, up 0.00% on the session, giving a market capitalisation of $111.1M. On trailing twelve-month figures it carries a trailing P/E of -8.12, a net margin of -6.7%. Its beta of 0.56 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-8.12
Price / Sales
0.53
Price / Book
9.17
EV / EBITDA
8.68
Gross margin
58.1%
Operating margin
-3.3%
Net margin
-6.7%
Return on equity
Debt / equity
3.87
Current ratio
0.72
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
742
IPO date
2014-10-06
Headquarters
Leipzig, SX, DE
About FamiCord AG

FamiCord AG engages in the collection, logistics, processing, and storage of stem cells from umbilical cord blood, umbilical cord tissue, and other postnatal tissues, serving as a full-service provider for cryopreservation. It also engages in the development of products and drugs derived from cells, tissues, and blood for medical applications. Additionally, FamiCord is active in Cell & Gene therapies and operates as a CDMO. The company was founded by Eberhard F. Lampeter on April 28, 1997 and is headquartered in Leipzig, Germany.

Comparable companies

FamiCord AG is most often compared with the following Healthcare names:

HLTRFHOFBFJUSHFKNTPFLDXHFPOLBFRCELSNZZFTOKIFVMTHF
More research on VTIAF
VTIAF technical analysis VTIAF TheEdge Score Compare against peers
Open full interactive analysis & DCF →